NO20003765L - Nye sulfonamidderivater som inhibitorer av benresorpsjon og som inhibitorer av celleadhesjon - Google Patents

Nye sulfonamidderivater som inhibitorer av benresorpsjon og som inhibitorer av celleadhesjon

Info

Publication number
NO20003765L
NO20003765L NO20003765A NO20003765A NO20003765L NO 20003765 L NO20003765 L NO 20003765L NO 20003765 A NO20003765 A NO 20003765A NO 20003765 A NO20003765 A NO 20003765A NO 20003765 L NO20003765 L NO 20003765L
Authority
NO
Norway
Prior art keywords
inhibitors
cell adhesion
bone resorption
sulfonamide derivatives
new sulfonamide
Prior art date
Application number
NO20003765A
Other languages
English (en)
Other versions
NO318795B1 (no
NO20003765D0 (no
Inventor
Anuschirwan Peyman
David Will
Jochen Knolle
Karl-Heinz Scheunemann
Denis Carniato
Jean-Francois Gourvest
Thomas R Gadek
Robert Mcdowell
Sarah Catherine Bodary
Robert Andrew Cuthbertson
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Publication of NO20003765D0 publication Critical patent/NO20003765D0/no
Publication of NO20003765L publication Critical patent/NO20003765L/no
Publication of NO318795B1 publication Critical patent/NO318795B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20003765A 1998-01-23 2000-07-21 Nye sulfonamidderivater og farmasoytisk preparat derav som inhibitorer av benresorpsjon og som inhibitorer av celleadhesjon og fremgangsmate for fremstilling derav NO318795B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23
PCT/EP1999/000242 WO1999037621A1 (en) 1998-01-23 1999-01-16 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Publications (3)

Publication Number Publication Date
NO20003765D0 NO20003765D0 (no) 2000-07-21
NO20003765L true NO20003765L (no) 2000-09-25
NO318795B1 NO318795B1 (no) 2005-05-09

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003765A NO318795B1 (no) 1998-01-23 2000-07-21 Nye sulfonamidderivater og farmasoytisk preparat derav som inhibitorer av benresorpsjon og som inhibitorer av celleadhesjon og fremgangsmate for fremstilling derav

Country Status (25)

Country Link
EP (1) EP1049677A1 (no)
JP (1) JP2002501054A (no)
KR (1) KR20010034319A (no)
CN (1) CN1177832C (no)
AP (1) AP1269A (no)
AR (1) AR014456A1 (no)
AU (1) AU752882B2 (no)
BG (1) BG104630A (no)
BR (1) BR9907735A (no)
CA (1) CA2318221A1 (no)
EA (1) EA003102B1 (no)
HR (1) HRP20000493A2 (no)
HU (1) HUP0100520A3 (no)
ID (1) ID26219A (no)
IL (1) IL137423A0 (no)
NO (1) NO318795B1 (no)
NZ (1) NZ505613A (no)
PL (1) PL341871A1 (no)
SK (1) SK10632000A3 (no)
TR (1) TR200002160T2 (no)
TW (1) TWI247742B (no)
UA (1) UA63990C2 (no)
WO (1) WO1999037621A1 (no)
YU (1) YU47200A (no)
ZA (1) ZA99476B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747784B2 (en) * 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1070707A1 (en) 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) * 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
AU2207001A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel compounds and process
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
ES2530056T3 (es) * 2004-03-24 2015-02-26 Shire Orphan Therapies Gmbh Nuevos compuestos para la inhibición de la angiogénesis y su uso
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
LT3262028T (lt) 2014-12-17 2022-01-10 Pimco 2664 Limited N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamido ir n-(-4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamido junginiai ir jų terapinis panaudojimas
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
JP3895792B2 (ja) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス 骨形成促進剤

Also Published As

Publication number Publication date
WO1999037621A1 (en) 1999-07-29
IL137423A0 (en) 2001-07-24
ZA99476B (en) 1999-08-05
AP2000001863A0 (en) 2000-09-30
AR014456A1 (es) 2001-02-28
JP2002501054A (ja) 2002-01-15
TWI247742B (en) 2006-01-21
CN1293662A (zh) 2001-05-02
BG104630A (en) 2001-04-30
HUP0100520A1 (hu) 2001-07-30
KR20010034319A (ko) 2001-04-25
YU47200A (sh) 2002-11-15
CN1177832C (zh) 2004-12-01
PL341871A1 (en) 2001-05-07
BR9907735A (pt) 2000-10-17
TR200002160T2 (tr) 2001-07-23
AP1269A (en) 2004-04-03
EA003102B1 (ru) 2002-12-26
UA63990C2 (uk) 2004-02-16
EP1049677A1 (en) 2000-11-08
HUP0100520A3 (en) 2002-11-28
NZ505613A (en) 2002-11-26
SK10632000A3 (sk) 2001-02-12
AU752882B2 (en) 2002-10-03
NO318795B1 (no) 2005-05-09
EA200000785A1 (ru) 2001-02-26
CA2318221A1 (en) 1999-07-29
AU2518199A (en) 1999-08-09
HRP20000493A2 (en) 2001-06-30
NO20003765D0 (no) 2000-07-21
ID26219A (id) 2000-12-07

Similar Documents

Publication Publication Date Title
NO20003765D0 (no) Nye sulfonamidderivater som inhibitorer av benresorpsjon og som inhibitorer av celleadhesjon
NO20003118D0 (no) Nye acylguanidinderivater som inhibitorer av benresorpsjon og som vitronektinreseptorantagonister
NO973400L (no) Nye iminoderivater som inhibitorer av benresorpsjon og vitronektinreseptorantagonister
NO996313D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
NO986180D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
NO973399D0 (no) Nye cykloalkylderivater som inhibitorer av benresorpsjon og vitronektinreseptorantagonister
DK1475377T3 (da) Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
NO975740D0 (no) Arylsulfonylaminobenzenderivater og deres anvendelse som faktor Xa-inhibitorer
DK0821671T3 (da) Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
NO20010534L (no) Amidderivater nyttige som inhibitorer av produksjon av cytokiner
DK0832082T3 (da) N-heteroaryl-pyridinsulfonamidderivater og deres anvendelse som endotelinantagonister
NO20012688D0 (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
NO20030885L (no) Inhibitorer av <alfa>4 styrt celleadhesjon
NO20010686D0 (no) Hydroksypipecolathydroksaminsyrederivater som MMP inhibitorer
DK0910573T3 (da) Nye aminosyrederivater og deres anvendelse som thrombininhibitorer
NO20011950L (no) Farmasöytiske blandinger som inneholder poly(ADP-ribose) glukohydrolaseinhibitorer og fremgangsmåter for anvendelse avsamme
DK1100792T3 (da) Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser
DK1150996T3 (da) Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
NO20016403D0 (no) Substituerte purinderivater som inhibitorer av celleadhesjon
NO20005301D0 (no) Pyrrolidiner som inhibitorer av neuraminidaser
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
NO20030820D0 (no) Anvendelse av vitamin D derivater som benresorpsjons inhibitorer
NO20006349D0 (no) Hydroksamsyrederivater som inhibitorer for produksjon av humant CD23 og av TNF-frigjöring
NO20003199D0 (no) Benzo(C)kinolizinderivater og deres anvendelse som 5- <alfa>reduktaseinhibitorer
DK0920330T3 (da) hCG og derivater som inhibitorer af matrixmetalloproteaser